Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 7, 2018

Primary Completion Date

September 30, 2025

Study Completion Date

October 31, 2025

Conditions

Locally Advanced Head and Neck Cancer

Interventions

DRUG

Pembrolizumab

Adding PD-1 inhibitor to the standard of care

Trial Locations (1)

RECRUITING

Kuwait Cancer Control Center, Kuwait City

All Listed Sponsors

lead

Kuwait Cancer Control Center

OTHER